Anti-thrombolytic effect of Salvia miltiorrhiza Bge extract in rats
Abstract
Purpose: To study the effects of Salvia miltiorrhiza Bge. extract (SMBE) on thrombosis in rats.
Methods: SMBE was obtained in water at 60 oC in an oven and then freeze-drying. Rats were divided into 6 groups of ten rats each: normal group, control group, reference group (aspirin 5 mg/kg) as well as three groups of SMBE groups (25, 50 and 100 mg/kg doses). Treatments were given orally once daily for 14 days. Common carotid artery FeCl3-induced thrombus and inferior vena cava thrombosis occlusion time, plasma concentrations of thromboxane B2 (TXB2) and 6-keto-prostaglandine F1α (6- keto-PGF1α) were measured in the rats.
Results: Compared with control group, all doses of SMBE significantly and dose-dependently prolonged thrombosis occlusion time, reduced the weight of thrombus and increased the inhibition rate of thrombus (p < 0.01). Plasma TXB2 concentration of all SMBE groups decreased dose-dependently (p < 0.05) while that of 6-keto-PGF1α increased with decrease in extract dose (p < 0.05). There was association between 6-keto-PGF1α/TXB2 and arterial or venous thrombus weight for all treatments, and also with occlusion time for SMBE treatment, but not for aspirin.
Conclusion: The results demonstrate the anti-thrombosis effect of SMBE in rats. This finding suggests that the plant is a potential therapy for thrombosis.
Keywords: Salvia miltiorrhiza Bge., Thrombosis, Thromboxane B2, 6-Keto-prostaglandin F1 alpha, Aspirin, Occlusion time
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
